Disc Medicine (IRON) vs MBX Biosciences (MBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MBX Biosciences (MBX) has outperformed Disc Medicine (IRON) over the past year, gaining 235.8% versus a loss of 13.5%. MBX Biosciences is the larger company by market cap ($2.55 billion vs $2.42 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRON | MBX |
|---|---|---|
| Share price | $63.12 | $52.95 |
| Market cap | $2.42B | $2.55B |
| 1-day change | +3.88% | -0.57% |
| YTD return | -23.47% | +68.83% |
| 1-year return | -13.53% | +235.75% |
| 5-year return | -45.55% | — |
| EPS (TTM) | $-6.58 | $-2.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-212.18M | $-87.00M |
| 52-week high | $99.50 | $72.64 |
| 52-week low | $40.00 | $12.94 |
| Distance from 52-week high | -36.56% | -27.11% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +63.45% | +78.11% |
| Average volume | 471.18K | 534.13K |
| Shares outstanding | 38.39M | 48.16M |
| Employees | 165 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MBX has outperformed IRON by 249.3 percentage points over the past year.
About Disc Medicine
IRON stock →Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 165 employees
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
IRON vs MBX FAQ
Which is bigger, Disc Medicine or MBX Biosciences?
MBX Biosciences (MBX) is larger, with a market capitalization of $2.55B compared with $2.42B for Disc Medicine (IRON).
Which stock has performed better over the past year, IRON or MBX?
MBX returned +235.75% over the past 12 months, compared with -13.53% for IRON (price return, excluding dividends). Past performance does not predict future results.
Are Disc Medicine and MBX Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.